Gordon Stein, CFO of CleanTech Lithium, explains why CTL acquired the 23 Laguna Verde licenses. Watch the video here.
Just a test
If you’ve been trading a while, you will know that the SP rises and falls on the MMs whim. They deliberately don’t share the buys with the market, but show the sells, panic sets in, day traders sell at a loss, then when the MMs have enough in their coffers, they started to raise the price, FOMO sets in, buyers race in ... and the circle starts again
A vaccine will not change the need for SNG 001.
1 A vaccine doesn’t work immediately, it needs some weeks to give protection
2 if you’re already infected, a vaccine won’t stop the symptoms from worsening
3 the whole country won’t be vaccinated and to vaccinate those who are eligible, will take months
SNG 001:
1 can prevent to symptoms from worsening
2 can be administered at home
3 doesn’t take weeks to build up immunity
4 worldwide studies confirm interferons work
5 it’s not just for covid-19, it’s expected to work on all variants
6 it’s not just for viral infections, Copd is an enormous market which is largely without a successful treatment
I expect those who hold their shares to be delighted with the returns. Keep calm and invest wisely, or don’t invest at all. DYOR
Already, we have 2 x 135k purchases on the books, and 1 at 25k ( a hangover from last night). Let’s hope the opening boost sets the tone for the rest of the day!
Ignore the derampers, far too many of them think they are pros at day trading. They sell hoping to buy back cheaper and then start sweating every time the SP moves up 1p and become more vocal ;)
If the Chinese are using it, then Synairgen will already be profiting from the transactions, but no one is declaring the stock is being consumed or being manufactured and shipped abroad, or that they have a manufacturer in place (GSK rumour only )
Just found this updated or released today :)
https://www.nihr.ac.uk/covid-19/urgent-public-health-studies-covid-19.htm?postid=24592
A randomised double-blind placebo-controlled trial to determine the safety and efficacy of inhaled SNG001 (IFNß-1a for nebulisation) for the treatment of patients with confirmed SARS-CoV-2 infection
Study type:
Interventional
Summary:
The purpose of this study is to confirm that SNG001 can prevent/limit the worsening of LRT illness in the context of SARS-CoV-2. Safety and efficacy will be assessed.
Chief Investigator:
Professor Tom Wilkinson University Hospital Southampton NHS Foundation Trust
Sponsor:
Synairgen Research Limited
Funder:
Synairgen Research Limited
IRAS Number:
281317
CPMS ID:
45382
Anyone notice the two 5 share sells after 4:30? That could be the MMs signalling a large move?
Interesting article on MMs on the following link:
www.investorschronicle.co.uk/shares/2019/10/24/shake-your-market-maker/
Posted an hour ago, key points listed below.
https://www.thepharmaletter.com/article/the-race-is-on-for-coronavirus-vaccines-and-treatments-current-r-d-status
Novel inhalation approaches:
Last but not least, the FDA has granted “emergency expanded access” to Bellerophon Therapeutics’ inhaled nitric oxide delivery system to ventilate coronavirus patients. The NOpulse system has completed a safety trial in healthy volunteers and a new clinical trial is underway in China in COVID-19 patients and as a preventive measure for healthcare providers. UK biotech Synairgen (AIM: SNG) was given the green light by MHRA for a Phase II trial in COVID-19 patients with its inhaled interferon, SNG001; previous studies have shown that it can reduce lung viral load and lung pathology in an in vivo swine flu driven model of viral pneumonia.
Synairgen/AstraZeneca
SNG001 (inhaled interferon-beta-1a)
Anti-inflammatory
21.03.20
Received approval from MHRA for phase II trial of its lead product SNG001 (inhaled interferon-beta-1a) in coronavirus (COVID-19) patients